Nothing Special   »   [go: up one dir, main page]

NO20084119L - Anvendelse av CK2-inhibitor til behandling og kjemostabilisering av tilbakevendende tumorer overfor anti-kreft-medikamenter - Google Patents

Anvendelse av CK2-inhibitor til behandling og kjemostabilisering av tilbakevendende tumorer overfor anti-kreft-medikamenter

Info

Publication number
NO20084119L
NO20084119L NO20084119A NO20084119A NO20084119L NO 20084119 L NO20084119 L NO 20084119L NO 20084119 A NO20084119 A NO 20084119A NO 20084119 A NO20084119 A NO 20084119A NO 20084119 L NO20084119 L NO 20084119L
Authority
NO
Norway
Prior art keywords
pharmaceutical combination
peptide
inhibitor
cancer treatment
treatment
Prior art date
Application number
NO20084119A
Other languages
English (en)
Other versions
NO341904B1 (no
Inventor
Yasser Perera Negrin
Lazaro Hiram Betancourt Nunez
Silvio Ernesto Perea Rodriguez
Arielis Rodriguez Ulloa
Jeovanis Gil Valdes
Yassel Ramos Gomez
Lila Rosa Castellanos Serra
Aniel Sanchez Puente
Jorge Fernandez De Cossio Dorta Duque
Boris Ernesto Acevedo Castro
Luis Javier Gonzalez Lopez
Vladimir Besada Perez
Daniel Fernando Alonso
Daniel Eduardo Gomez
Original Assignee
Biorec Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40134932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084119(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biorec Bv filed Critical Biorec Bv
Publication of NO20084119L publication Critical patent/NO20084119L/no
Publication of NO341904B1 publication Critical patent/NO341904B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Foreliggende oppfinnelse angår en farmasøytisk kombinasjon som inneholder en Caseinkinase 2 (CK2) peptidinhibitor (navngitt P15) sammen med standard kjemoterapeutiske legemidler anvendt ved kreftbehandling og som administreres sammen, separat eller sekvensielt. De kjemoterapeutiske legemidlene inkluderer cisplatin, taxol, alkaloider fra Vinca, 5-fluoruracil, doxorubicin, cyklofosfamid, etoposid, mitomicin C, imatinib, iressa og velcade (vortezomib). Synergien mellom P15-peptidet og antikreftlegemidlene gir en effektiv konsentrasjon av hvert cytostatisk legemiddel i kombinasjonen som er fra 10 til 100 ganger lavere enn den for hvert cytostatisk legemiddel alene. Den farmasøytiske kombinasjonen beskrevet ifølge oppfinnelsen fremviser lav toksisitet sammenlignet med den som rapporteres fra antikreftterapeutiske midler og derfor representerer den en viktig fordel ved dens anvendelse ved kreftbehandling. Videre fører den sekvensielle administrasjonen av denne farmasøytiske kombinasjonen gjennom forhåndsbehandling med P15-peptidet til en kjemosensibilisering av refraktære tumorer ovenfor antikreftterapetutiske midler.
NO20084119A 2006-02-28 2008-09-29 Farmasøytisk kombinasjon for simultan, separat eller sekvensiell administrasjon NO341904B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20060049A CU23511B6 (es) 2006-02-28 2006-02-28 Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
PCT/CU2007/000010 WO2007098719A1 (es) 2006-02-28 2007-02-28 Combinación farmaceutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas

Publications (2)

Publication Number Publication Date
NO20084119L true NO20084119L (no) 2008-11-25
NO341904B1 NO341904B1 (no) 2018-02-19

Family

ID=40134932

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084119A NO341904B1 (no) 2006-02-28 2008-09-29 Farmasøytisk kombinasjon for simultan, separat eller sekvensiell administrasjon

Country Status (23)

Country Link
US (3) US8871725B2 (no)
EP (1) EP1997506B8 (no)
JP (2) JP5733880B2 (no)
KR (1) KR101454866B1 (no)
CN (1) CN101432012B (no)
AR (1) AR059645A1 (no)
AU (1) AU2007219572B2 (no)
BR (1) BRPI0708307B1 (no)
CA (1) CA2642943C (no)
CL (1) CL2015001086A1 (no)
CU (1) CU23511B6 (no)
CY (1) CY1114686T1 (no)
DO (1) DOP2007000040A (no)
HK (1) HK1132451A1 (no)
MX (1) MX2008011141A (no)
MY (1) MY150135A (no)
NO (1) NO341904B1 (no)
PE (1) PE20081191A1 (no)
PL (1) PL1997506T3 (no)
RU (1) RU2396974C2 (no)
UY (1) UY30175A1 (no)
WO (1) WO2007098719A1 (no)
ZA (1) ZA200807323B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
EP3866804A4 (en) 2018-10-19 2022-08-03 Senhwa Biosciences, Inc. COMBINATIONS FOR IMMUNE MODULATION IN THE TREATMENT OF CANCER
CN109875998B (zh) * 2019-01-24 2021-09-03 武汉大学 酰胺类生物碱在制备肿瘤化疗药物增敏剂中的应用及抗肿瘤药物组合物
CN110448699B (zh) * 2019-06-12 2022-03-11 天津医科大学 包含功能性多肽修饰七甲川花菁素类染料的肿瘤细胞核靶向载药纳米粒子及制备方法
CU20200103A7 (es) * 2020-12-18 2022-07-08 Ct Ingenieria Genetica Biotecnologia Péptido sintético para la inducción de inmunidad antitumoral y antiviral
CN114712377B (zh) * 2022-04-26 2023-08-15 江苏师范大学 断血流皂苷a在制造药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
US7351729B2 (en) * 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
US20060014987A1 (en) * 2003-07-07 2006-01-19 Lan Huang Synthesis of beta-elemene, intermediates thereto, analogues and uses thereof
WO2005049030A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
KR20060123463A (ko) * 2003-12-09 2006-12-01 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 면역 반응을 억제하거나 증식성 장애를 치료하는 방법들
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas

Also Published As

Publication number Publication date
US8871725B2 (en) 2014-10-28
MY150135A (en) 2013-11-29
AR059645A1 (es) 2008-04-16
US20150030700A1 (en) 2015-01-29
BRPI0708307B8 (no) 2021-05-25
CL2015001086A1 (es) 2016-05-13
CU23511B6 (es) 2010-04-13
KR20090030251A (ko) 2009-03-24
ZA200807323B (en) 2009-05-27
PE20081191A1 (es) 2008-09-24
US20150111832A1 (en) 2015-04-23
US9226946B2 (en) 2016-01-05
RU2008138534A (ru) 2010-04-10
PL1997506T3 (pl) 2013-04-30
EP1997506A1 (en) 2008-12-03
JP2013231065A (ja) 2013-11-14
CY1114686T1 (el) 2016-10-05
CN101432012B (zh) 2013-01-02
NO341904B1 (no) 2018-02-19
AU2007219572A1 (en) 2007-09-07
EP1997506B8 (en) 2013-02-20
CN101432012A (zh) 2009-05-13
MX2008011141A (es) 2009-01-26
CA2642943C (en) 2013-07-23
WO2007098719A1 (es) 2007-09-07
HK1132451A1 (en) 2010-02-26
EP1997506B1 (en) 2012-12-05
RU2396974C2 (ru) 2010-08-20
BRPI0708307A2 (pt) 2011-05-24
AU2007219572B2 (en) 2012-07-05
DOP2007000040A (es) 2007-09-30
UY30175A1 (es) 2008-01-31
US9278118B2 (en) 2016-03-08
JP2009528306A (ja) 2009-08-06
CA2642943A1 (en) 2007-09-07
JP5733880B2 (ja) 2015-06-10
KR101454866B1 (ko) 2014-11-04
US20090130228A1 (en) 2009-05-21
BRPI0708307B1 (pt) 2019-07-23

Similar Documents

Publication Publication Date Title
NO20084119L (no) Anvendelse av CK2-inhibitor til behandling og kjemostabilisering av tilbakevendende tumorer overfor anti-kreft-medikamenter
ES2622559T3 (es) Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico
RU2438664C2 (ru) Синергическая фармацевтическая комбинация для лечения рака
BRPI0721626A2 (pt) combinaÇço farmacÊutica sinergÍstica para o tratamento de cÂncer
US8492397B2 (en) Aminopyridine derivatives having Aurora A selective inhibitory action
AU2017226389A2 (en) Preparation and composition for treatment of malignant tumors
Thongnuanjan et al. Fenofibrate reduces cisplatin-induced apoptosis of renal proximal tubular cells via inhibition of JNK and p38 pathways
EP4096651A1 (en) Compounds and uses thereof
ES2848706T3 (es) Terapia de combinación contra el cáncer usando un compuesto azabicíclico
Min et al. Autophagy as a potential target for sarcoma treatment
Huo et al. Aqueous extract of Cordyceps sinensis potentiates the antitumor effect of DDP and attenuates therapy-associated toxicity in non-small cell lung cancer via IκBα/NFκB and AKT/MMP2/MMP9 pathways
US8481503B2 (en) Combination cancer therapy with an AKT inhibitor and other anticancer agents
BR112019016668A2 (pt) métodos para aumentar a concentração de plasma de durd e para inibir timidilato-sintase (ts) em um indivíduo humano.
US20070280944A1 (en) Use of 5,10-Methylene Tetrahydrofolate for the Treatment of Cancer
Tuttle et al. Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells
RU2346686C2 (ru) Комбинации, включающие эпотилоны и антиметаболиты
CA3119395A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
Du Bois et al. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC–IV (AGO-OVAR protocol OVAR-8)
To et al. Synergistic interaction between platinum-based antitumor agents and demethylcantharidin
Ge et al. Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells
Badary et al. Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL
Salako et al. Screening of Amodiaquine for its in vitro Anti-cancer Activity on Breast Cancer Cell Lines-a Case Study for Drug Reprofiling
Mattos Marine Natural Products as Molecular Probes to Study Cancer Cell Stress and Proteostasis
Al Khafaji et al. Anticancer and Antioxidant Effects of Sitagliptin and Linagliptin against Lung Cancer Cell Lines (an In vitro Study).
BR112015021448B1 (pt) Uso do peptídeo gliadina no tratamento de câncer

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees